TTR Genotype

If a parent, sibling, or grandparent had unexplained heart failure late in life, stubborn carpal tunnel surgery in middle age, or a slowly progressive neuropathy nobody could name, the answer may be sitting in a single gene. TTR (transthyretin) genotyping reads the gene that codes for a liver protein that, in certain inherited forms, can misfold and slowly build up inside the heart and nerves over decades.

A standard cardiology workup, a normal cholesterol panel, even a clean stress test will not tell you whether you carry one of these variants. This is a once-in-a-lifetime test that resolves a specific question: do you carry an inherited variant that meaningfully raises your odds of a disease called ATTR amyloidosis, and if so, which one.

What This Test Reads

The TTR gene sits on chromosome 18 and codes for transthyretin, a four-subunit protein the liver releases into the blood. When the gene carries certain changes, the four-subunit assembly becomes unstable, breaks apart, and the loose pieces clump together in tissues as amyloid deposits. The heart muscle and peripheral nerves are the two organs most often affected, though the gut, kidneys, and the median nerve at the wrist can also be involved.

Researchers have catalogued more than 130 different variants in the TTR gene that increase the rate at which these deposits form. The disease they cause is called hereditary ATTR amyloidosis, or ATTRv, and it is passed down in an autosomal dominant pattern, meaning one copy from one parent is enough to carry the risk. There is also a non-inherited form called wild-type ATTR (ATTRwt), which occurs without any gene variant and shows up in older adults.

The Variants That Matter Most

Not all TTR variants behave the same way. A few are common enough, and well-studied enough, that they deserve specific attention. The frequency of each one varies sharply by ancestry and region, which is why the clinical meaning of your result depends partly on who your ancestors were.

What this means for you: the same lab report saying you carry a TTR variant can mean very different things depending on which specific variant it is. Val122Ile and the heart, Val30Met and the nerves, Ser77Tyr and a predominantly neurologic picture are not interchangeable risks. Your result is the start of a workup, not the end of one.

Heart Disease Risk

The strongest cardiac signal comes from Val122Ile. In a study of about 2,960 middle-aged Black adults, 119 participants (4%) were heterozygous carriers, and carriers had a significantly higher burden of chronic heart muscle injury and a greater risk of developing heart failure during follow-up. A separate community-based analysis found that Val122Ile carriers had higher rates of heart failure, cardiovascular death, and death from any cause.

In the UK Biobank, the overall prevalence of likely-pathogenic or pathogenic TTR variants was 0.1% (473 of 469,789 participants), and just 0.02% in participants of European ancestry, but in participants with African ancestry the carrier rate climbed to 4.3% (321 of 7,533 individuals). Carrier status was linked to a higher risk of heart failure. Among older adults already diagnosed with cardiac amyloidosis, the picture flips toward the gene more than people expect: in one referral cohort of patients 70 and older with ATTR-CM, 20.7% carried a pathogenic TTR variant, and Val122Ile accounted for 77.7% of those cases.

Nerve and Multisystem Disease Risk

Val30Met has been the most studied neuropathy variant. It causes a slowly progressive sensory and motor neuropathy that can be accompanied by autonomic problems (lightheadedness, gut symptoms, sexual dysfunction) and, in many carriers, heart involvement as well. Non-V30M variants often produce a mixed or cardiomyopathy-dominant picture, and some, like Lys55Asn, cause a severe, rapidly progressive neuropathy with prominent gastrointestinal dysfunction.

A large analysis of TTR variants across diverse populations found that amyloidogenic TTR mutations track with a long list of conditions in carriers, including heart failure, atrial fibrillation, carpal tunnel syndrome, dysphagia, and intestinal disease, with the specific pattern varying by ancestry. A phenome-wide analysis of TTR found 26 traits associated with non-coding TTR variants, including chronic ischemic heart disease, heart failure, atrial fibrillation, dysphagia, and anxiety.

Penetrance and the Carrier Paradox

Carrying a pathogenic TTR variant does not guarantee you will develop the disease. The technical word for this is penetrance, and for most TTR variants it is incomplete and age-dependent. Many carriers reach old age without symptoms; others develop disease in their forties, sixties, or eighties. A community-based study made this concrete: V122I carriers showed early imaging that looked close to normal, yet over years they accumulated chronic myocardial injury and developed heart failure at higher rates than non-carriers.

The practical implication is that a positive result is an invitation to start watching, not a verdict. Population sequencing has consistently shown that pathogenic TTR variants are far more common than diagnosed disease, which means a substantial share of carriers are walking around undiagnosed, and a substantial share of carriers will never become symptomatic. Both can be true at once.

One-Time Result, Lifetime Action

This is a one-time test. Your germline DNA does not change, so the genotype you receive at 40 is the same one you would have received at 4 or 84. There is nothing to retrace and no trend to track in the genotype itself. The value comes from integrating the result into decisions you make over the next several decades, not from repeating the test.

If you carry a pathogenic variant, the testing cadence that matters is the cadence of phenotype monitoring: the labs and imaging that look for early evidence of amyloid deposition in the heart and nerves. This typically includes regular cardiac evaluation (echocardiography, cardiac biomarkers like NT-proBNP and high-sensitivity troponin), a neurology assessment if symptoms emerge, and consideration of cardiac scintigraphy or MRI as the years pass. Disease-modifying drugs (TTR stabilizers and gene-silencing therapies) now exist, and their effectiveness depends on starting before the heart and nerves are heavily damaged.

Decision Pathway for an Unexpected Result

If your TTR genotype comes back positive for a pathogenic or likely-pathogenic variant, several things should happen next, in roughly this order:

• Confirm and characterize the variant: ask whether the specific variant call is well-established as pathogenic, of uncertain significance, or population-specific, and whether a confirmatory method is warranted.
• Get a cardiac baseline: an echocardiogram, an ECG, and cardiac biomarkers establish where your heart is now. Specialists may add cardiac MRI or bone scintigraphy (a nuclear scan that picks up cardiac TTR deposits).
• Get a neurology baseline if symptoms suggest it: any tingling, numbness, autonomic symptoms, or unexplained carpal tunnel surgery deserves a neurology evaluation.
• Talk with biological family members: first-degree relatives (parents, siblings, children) each have a 50% chance of carrying the same variant. Many of them will benefit from testing too.

A genetic counselor can be useful both before and after testing, particularly if there is a strong family history or if the variant carries uncertain meaning. For people who develop early signs of cardiac or neurologic involvement, evaluation by a specialist who treats ATTR amyloidosis (typically a cardiologist or neurologist at a center with experience in the disease) is the next step.

When Results Can Be Misleading

• Panel coverage limits: a TTR genotyping panel detects the specific variants it is designed to detect. A negative result rules out the variants on the panel; it does not rule out rare or novel variants elsewhere in the gene.
• Ancestry-specific allele frequencies: a variant common in one population may be rare in another. Val122Ile is most informative for people of African ancestry; Val30Met for those with Portuguese, Japanese, Swedish, or Balearic roots; Ser77Tyr for Yemenite Jewish ancestry. The clinical meaning of a result depends partly on where your ancestors lived.
• Variants of uncertain significance: occasionally a TTR variant is reported whose clinical meaning is not yet established. These deserve discussion with a genetic counselor rather than action based on the result alone.
• Direct-to-consumer reports: a 23andMe-style report may flag a TTR variant but is not a clinical-grade assay. A clinical confirmation is appropriate before acting on a consumer genetic finding.

How This Test Fits the Bigger Picture

TTR genotyping answers one question: do you carry an inherited variant that raises your risk of amyloid disease. It does not measure transthyretin protein levels in your blood, it does not image your heart, and it does not test your nerves. Those are separate measurements that become more important once you know your genotype. The genotype tells you whether to look harder; the phenotype tests tell you whether anything has started.